Open Access

Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis.

Congress Session

About the speaker

Professor Josef Veselka

University Hospital Motol, CardioVascular Center, Prague (Czechia)
2 presentations
0 follower

4 more presentations in this session

State of the Art in the treatment of hypertrophic cardiomyopathy

Speaker: Professor I. Olivotto (Florence, IT)


Earlier surgical myectomy vs. waiting for a Class I indication is associated with improved long-term survival in symptomatic hypertrophic obstructive cardiomyopathy patients

Speaker: Doctor M. Desai (Cleveland, US)


A novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)

Speaker: Doctor G. Norrish (London, GB)


Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study

Speaker: Professor A. Wang (Durham, US)


Access the full session

Novel therapeutic targets in hypertrophic cardiomyopathy

Speakers: Professor J. Veselka, Professor I. Olivotto, Doctor M. Desai, Doctor G. Norrish, Professor A. Wang

About the event



31 August - 4 September 2019

Sessions Presentations

Related content

Open Access

Multimodality imaging to quantify low-flow low-gradient aortic stenosis.

29 August 2021

Open Access

Multimodality imaging to determine the source of cardiac embolism.

29 August 2021

Open Access

Infective endocarditis causing by HACEK gram-negative bacteria presented with fever of unknow origin: The important of early echocardiogram.

27 August 2021

This platform is supported by

logo Novo Nordisk